Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowResearchers from Purdue University and its College of Veterinary Medicine are studying an experimental vaccine therapy to treat often-fatal solid tumors in dogs.
The clinical trial, announced last month, focuses on Beverly, Massachusetts-based Akston Biosciences Corp.’s Ambifect immune-enhancing therapy, with Purdue researchers looking to enroll about 10 dogs.
Ambifect is an injected therapy designed to stimulate the dog’s immune system to produce antibodies targeting the PD-L1 protein. That protein helps prevent the body’s natural defenses from attacking cancer cells.
A dog suffering from such tumors currently would be treated through radiation, chemotherapy or surgery, if the tumor is operable. Akston said Ambifect holds the potential to make those traditional treatments, which are far more costly, less frequent.
“The new vaccine trial is a way to train the immune system to make these antibodies by itself,” said Dr. Nikolaos Dervisis, associate professor of oncology at the Purdue College of Veterinary Medicine. “If you think of the rabies vaccination, that you give a few doses and then the immunity is there. … Perhaps in the future, you need to just boost every few months or every year.”
The purpose of the first trial is to assess the therapy’s safety and tolerability, with secondary objectives to identify initial signs of efficacy and to study biomarkers for response.
Purdue said the dogs in the trial will have an average age of about 10, diagnosed with solid tumors including soft-tissue sarcoma, melanoma and mast cell tumors.
“We’re enrolling dogs with a variety of cancers,” said Dr. Shawna Klahn, associate professor of oncology in veterinary medicine at Purdue. “We’re looking at, is there any group of cancers, or any cancer in particular that this works well in?”
She said the next phase would then focus on those cancers to look more closely at efficacy.
Touting itself as a biotech company built for pets, Akston is part of a growing market for new medicines, marketed and sold to “pet parents.” In 2023, the company pivoted to fully focus on animal health, having previously worked on products designed for people, such as COVID-19 vaccines and diabetes treatments.
“We should really be trying to bring these biotech advances to our pets because we share biology with them and in many types of cancer, including bladder cancer and some sarcomas, there’s actually a really strong connection between us and our friendly four-legged friends,” said Todd Zion, co-founder and CEO of Akston.
The pet industry is huge, with 51% of U.S. households owning a dog and 37% of U.S. households owning a cat, according to the American Pet Products Association. Pet industry expenditures in the United States totaled $152 billion in 2024, with a projected increase to $157 billion in sales for 2025.
The new Ambifect trial builds on another Purdue-led clinical trial looking at Akston’s monoclonal antibody for treatment of dogs with bladder cancer. Akston said that treatment is on track for conditional approval from the U.S. Department of Agriculture, or USDA, in 2027.
The company said it is targeting 2029 for USDA conditional licensure of the Ambifect immune-enhancing therapy.
Approval, the researchers noted, can move something like dog years for new canine medicines.
“It still does take some time, but it can move quicker than in people,” Klahn said.
Please enable JavaScript to view this content.
Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.